专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012011778A3 CANCER DIAGNOSIS KIT AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER 审中-公开
标题翻译：癌症诊断试剂盒和药物组合物预防或治疗癌症
公开(公告)号：WO2012011778A3
公开(公告)日：2012-05-24
申请号：PCT/KR2011005433
申请日：2011-07-22
申请人： KOREA RES INST OF BIOSCIENCE , CHUNG KYUNG SOOK , WON MI SUN , AHN JI WON , KIM YOUNG JOO , SONG EUN YOUNG , YEOM YOUNG IL , LEE HEE GU
发明人： CHUNG KYUNG SOOK , WON MI SUN , AHN JI WON , KIM YOUNG JOO , SONG EUN YOUNG , YEOM YOUNG IL , LEE HEE GU
IPC分类号： C12Q1/68 , A61K48/00 , C12N15/12 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/574
摘要： The present invention relates to a composition for cancer diagnosis having a formulation for measuring the expression level of Chromosome 10 open reading frame 81 (C10orf81) gene mRNA or protein thereof, a kit for cancer diagnosis having the composition, a method for providing information on cancer diagnosis including a step for measuring the expression level of C10orf81 gene mRNA or the expression level of protein coded by the gene, and a method for screening pharmaceutical compositions for the prevention or the treatment of cancer including an expression inhibitor for the C10orf81 gene or an activity inhibitor for the protein thereof, and therapeutic agents for cancer. The present invention enables an accurate diagnosis of cancer by providing genes specific to stomach cancer, liver cancer, colorectal cancer, lung cancer, or prostate cancer, and diagnostic markers for determining the metastasis and prognosis of the cancer, and can be useful in the diagnosis and prognosis management of cancer. Also, the present invention enables the development of new bio-medicines having fewer side effects and customized anticancer drugs by providing a cancer-specific therapeutic agent capable of inhibiting the gene.
摘要翻译：本发明涉及用于癌症诊断的组合物，其具有用于测量染色体10开放阅读框81（C10orf81）基因mRNA或其蛋白质的表达水平的制剂，具有该组成的癌症诊断用试剂盒，提供癌症信息的方法诊断包括测量C10orf81基因mRNA的表达水平的步骤或由该基因编码的蛋白质的表达水平的步骤，以及用于筛选用于预防或治疗癌症的药物组合物的方法，包括用于C10orf81基因的表达抑制剂或活性其蛋白质的抑制剂和癌症治疗剂。本发明能够通过提供对胃癌，肝癌，结肠直肠癌，肺癌或前列腺癌特异性的基因和用于确定癌症的转移和预后的诊断标记物来准确诊断癌症，并且可用于诊断和癌症的预后管理。此外，通过提供能够抑制该基因的癌症特异性治疗剂，本发明能够开发副作用较少的新生物药物和定制的抗癌药物。

2. 发明申请

WO2010067984A2 NOVEL BIOMARKER FOR LIVER CANCER AND APPLICATIONS FOR SAME 审中-公开
标题翻译：新的肝癌生物标志物及其应用
公开(公告)号：WO2010067984A2
公开(公告)日：2010-06-17
申请号：PCT/KR2009007202
申请日：2009-12-03
申请人： KOREA RES INST OF BIOSCIENCE , SONG EUN YOUNG , LEE HEE GU , YEOM YOUNG IL , JI NA YOUNG , LEE JUNG IL , KANG MIN A , KIM YOUNG JOO , KANG YOON HEE , KIM JAE WHA
发明人： SONG EUN YOUNG , LEE HEE GU , YEOM YOUNG IL , JI NA YOUNG , LEE JUNG IL , KANG MIN A , KIM YOUNG JOO , KANG YOON HEE , KIM JAE WHA
IPC分类号： C12Q1/68 , C12N15/12 , G01N33/574
CPC分类号： C07K14/4748 , C12Q1/6886 , C12Q2600/158 , G01N33/57438 , G01N2800/50
摘要： The present invention relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer. The markers of the present invention can be used for the accurate diagnosis and prognosis of liver cancer.
摘要翻译：本发明涉及可用作肝癌诊断的新型标志物的基因的阐明以及使用其的肝癌的诊断和预后测量。更具体而言，涉及一种诊断试剂盒，其能够使用测定选自由S100P，NK4，CCL20，CSPG2等组成的肝癌诊断标志物组中的至少一个基因的表达量的制剂，进行肝癌的诊断和预后测定。 PLA12，MMP12，ESM-1，ABHD7，HCAPG，CXCL-3，Col5A2，MAGEA，GSN，CDC2，CST1，MELK，ATAD2，FAP和MSN和/或使用其诊断和预测肝癌的方法。已经发现使用从本发明的相同肝癌患者采集的正常肝组织和肝癌组织，并且代表了其准确性和可靠性作为肝癌标志物已经大大提高的标志物。本发明的标记物可用于肝癌的准确诊断和预后。

3. 发明申请

WO2007074966A1 MAC-2BP AS A MARKER FOR THE DIAGNOSIS OF GASTRIC CANCER 审中-公开
标题翻译： MAC-2BP作为胃癌诊断标记
公开(公告)号：WO2007074966A1
公开(公告)日：2007-07-05
申请号：PCT/KR2006/003802
申请日：2006-09-25
申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , LEE, Hee Gu , PARK, Yuk Pheel , KIM, Jae Wha , SONG, Eun Young , YOON, Do Young , YEOM, Young Il , CHOI, Seung-Chul
发明人： LEE, Hee Gu , PARK, Yuk Pheel , KIM, Jae Wha , SONG, Eun Young , YOON, Do Young , YEOM, Young Il , CHOI, Seung-Chul
IPC分类号： G01N33/574
CPC分类号： G01N33/57446
摘要： Disclosed is a diagnostic kit for gastric cancer. It comprises an agent capable of detecting and quantitatively assaying the gastric cancer marker Mac-2BP (Mac-2 binding protein) . Also, a method for detecting the gastric cancer marker using the kit is disclosed.
摘要翻译：公开了一种胃癌诊断试剂盒。它包括能够检测和定量测定胃癌标记物Mac-2BP（Mac-2结合蛋白）的试剂。另外，公开了使用该试剂盒检测胃癌标记物的方法。

4. 发明申请

WO2012105764A2 APPARATUS AND METHOD FOR PROVIDING APPLICATION AUTO-INSTALL FUNCTION IN DIGITAL DEVICE 审中-公开
标题翻译：用于在数字设备中提供应用自动安装功能的装置和方法
公开(公告)号：WO2012105764A2
公开(公告)日：2012-08-09
申请号：PCT/KR2012/000551
申请日：2012-01-20
申请人： SAMSUNG ELECTRONICS CO., LTD. , KWON, Joon-Hwan , PARK, Gyu-Tae , SONG, Eun-Young
发明人： KWON, Joon-Hwan , PARK, Gyu-Tae , SONG, Eun-Young
IPC分类号： G06F9/44 , G06F15/16
CPC分类号： G06F13/102 , G06F9/4415 , H04M1/72525 , H04M1/72533
摘要： An apparatus and method install an application in a digital device. An apparatus for providing a connection program to a desired peripheral device in a digital device includes a communication unit for receiving system information from a peripheral device and transmitting a connection program list, a program detecting unit for analyzing the received system information and creating the connection program list executable in the peripheral device, and a control unit for transmitting the created connection program list to the peripheral device.
摘要翻译：一种装置和方法在数字装置中安装应用程序。一种用于向数字设备中的期望的外围设备提供连接程序的设备包括：通信单元，用于从外围设备接收系统信息并发送连接节目列表;程序检测单元，用于分析接收到的系统信息并创建连接程序在外围设备中可执行的列表，以及用于将创建的连接节目列表发送到外围设备的控制单元。

5. 发明申请

WO2012011777A2 KIT FOR DIAGNOSING COLORECTAL CANCER AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF COLORECTAL CANCER 审中-公开
标题翻译：用于诊断颜色性癌症和药物组合物的工具包，用于预防或治疗色素性癌症
公开(公告)号：WO2012011777A2
公开(公告)日：2012-01-26
申请号：PCT/KR2011005431
申请日：2011-07-22
申请人： KOREA RES INST OF BIOSCIENCE , CHUNG KYUNG SOOK , WON MI SUN , KIM YOUNG JOO , SONG EUN YOUNG , AHN JI WON , YEOM YOUNG IL , LEE HEE GU , JANG YEO-JIN
发明人： CHUNG KYUNG SOOK , WON MI SUN , KIM YOUNG JOO , SONG EUN YOUNG , AHN JI WON , YEOM YOUNG IL , LEE HEE GU , JANG YEO-JIN
IPC分类号： C12Q1/68 , A61P35/00 , C12N15/12 , G01N33/574
CPC分类号： G01N33/57419 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention relates to: a composition for diagnosing colorectal cancer containing a formulation for measuring the expression level of a chromosome 1 open reading frame 135 (C1orf135) gene mRNA or the protein thereof; a kit for diagnosing colorectal cancer containing the composition; a method for providing information on diagnosis of colorectal cancer, the method comprising a step for measuring the expression level of a C1orf135 gene mRNA or the expression level of the protein coded by the gene; a pharmaceutical composition for the prevention or the treatment of colorectal cancer, the composition comprising an expression inhibitor for a C1orf135 gene or an activity inhibitor for the protein thereof; and a method for screening a therapeutic agent for colorectal cancer. The present invention enables the accurate diagnosis of colorectal cancer by providing a gene specific to colorectal cancer, and a diagnostic marker for determining the metastasis and prognosis of colorectal cancer, and can be useful in the diagnosis and prognosis management of colorectal cancer. Also, the present invention enables the development of new bio-medicines having fewer side effects and customized anticancer drugs by providing a colorectal cancer-specific therapeutic agent capable of inhibiting the gene.
摘要翻译：本发明涉及：用于诊断结肠直肠癌的组合物，其含有用于测量染色体1开放阅读框135（C1orf135）基因mRNA或其蛋白质的表达水平的制剂; 用于诊断含有该组合物的结肠直肠癌的试剂盒; 提供关于结肠直肠癌诊断的信息的方法，所述方法包括测定C1orf135基因mRNA的表达水平或由所述基因编码的蛋白质的表达水平的步骤。用于预防或治疗结肠直肠癌的药物组合物，所述组合物包含C1orf135基因的表达抑制剂或其蛋白质的活性抑制剂; 以及筛选结直肠癌治疗剂的方法。本发明能够通过提供对结肠直肠癌特异性的基因和用于确定结肠直肠癌的转移和预后的诊断标记物来准确诊断结肠直肠癌，并且可用于结肠直肠癌的诊断和预后管理。此外，通过提供能够抑制该基因的结肠直肠癌特异性治疗剂，本发明使得能够开发具有较少副作用的新生物药物和定制的抗癌药物。

6. 发明申请

WO2011065677A3 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER 审中-公开
标题翻译：治疗癌症的药物组合物
公开(公告)号：WO2011065677A3
公开(公告)日：2011-11-03
申请号：PCT/KR2010007600
申请日：2010-11-01
申请人： KOREA RES INST OF BIOSCIENCE , WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG JOO , HONG HYE KYUNG , YEOM YOUNG IL , YUN CHAE OK , OH YU KYUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , KIM MOON HEE , JUNG KYEONG-EUN
发明人： WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG JOO , HONG HYE KYUNG , YEOM YOUNG IL , YUN CHAE OK , OH YU KYUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , KIM MOON HEE , JUNG KYEONG-EUN
IPC分类号： A61K31/7105 , A61K31/711 , A61P35/00
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/711 , A61K31/713 , C12N2310/531
摘要： The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
摘要翻译：本发明提供用于治疗癌症的药物组合物，其包含选自用于编码与FLJ25416基因的转录物（mRNA转录物）的碱基序列互补结合的小干扰RNA（siRNA）的脱氧核糖核酸（DNA）中的至少一种，序列号3，序列号5和序列号7以抑制FLJ25416基因的细胞内表达，抑制FLJ25416基因表达的反义RNA和抑制FLJ25416基因表达的短发夹RNA（shRNA）。由于本发明的与FLJ25416基因，反义RNA和shRNA的转录物（mRNA转录物）的碱基序列互补的siRNA抑制已知表达癌细胞，从而杀死癌细胞，本发明的组合物可以用作新型的抗癌剂。

7. 发明申请

WO2010047448A1 DIAGNOSTIC KIT OF COLON CANCER USING COLON CANCER RELATED MARKER,AND DIAGNOSTIC METHOD THEREOF 审中-公开
标题翻译：使用结肠癌相关标记的结肠癌诊断套件及其诊断方法
公开(公告)号：WO2010047448A1
公开(公告)日：2010-04-29
申请号：PCT/KR2009/002039
申请日：2009-04-20
申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , SONG, Eun Young , LEE, Hee gu , YEOM, Young Il , KIM, Jae Wha , JI, Na Young , CHUNG, Kyung-Sook , WON, Misun , KIM, Seon-Young , KIM, Joo Heon , KIM, Young Ho , CHUN, Ho Kyung
发明人： SONG, Eun Young , LEE, Hee gu , YEOM, Young Il , KIM, Jae Wha , JI, Na Young , CHUNG, Kyung-Sook , WON, Misun , KIM, Seon-Young , KIM, Joo Heon , KIM, Young Ho , CHUN, Ho Kyung
IPC分类号： C12N15/10
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability.
摘要翻译：本发明涉及用于诊断结肠癌的组合物。所述组合物包含至少一种用于测量至少一种对结肠癌特异性基因的mRNA或蛋白质表达水平的标记物。它可以筛选出仅在结肠癌组织或血液中过度表达的基因。本发明可以同时定量分析基因的mRNA表达水平和由该基因编码的蛋白质的表达水平，从而以高可靠性诊断早期的结肠癌。

8. 发明申请

WO2009131365A2 CST1, DCC1, IFITM1 OR MELK AS MARKERS FOR DIAGNOSING STOMACH CANCER 审中-公开
标题翻译： CST1，DCC1，IFITM1或MELK作为诊断STOMACH癌症的标记
公开(公告)号：WO2009131365A2
公开(公告)日：2009-10-29
申请号：PCT/KR2009002084
申请日：2009-04-21
申请人： KOREA RES INST OF BIOSCIENCE , LEE HEE GU , SONG EUN YOUNG , KANG MIN AH , KIM JONG TAE , CHOI EUN HWA , YOON HYO RAN , KIM JAE WHA
发明人： LEE HEE GU , SONG EUN YOUNG , KANG MIN AH , KIM JONG TAE , CHOI EUN HWA , YOON HYO RAN , KIM JAE WHA
IPC分类号： C12N15/12 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/57446 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N2500/04
摘要： The present invention is related to stomach cancer-specific biomarkers CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase), and more specifically, is related to a composite for diagnosis of stomach cancer containing a preparation to measure the level of expression of CST1, DCC1, IFITM1 or MELK, a kit containing said composites, a method of detecting said marker and a screening method for treatment of stomach cancer using said marker.
摘要翻译：本发明涉及胃癌特异性生物标志物CST1（半胱氨酸蛋白酶抑制剂，2型家族），DCC1（姐妹染色单体内聚同系物1中有缺陷），IFITM1（干扰素诱导的跨膜蛋白1）或MELK（母体亮氨酸亮氨酸拉链激酶）更具体地，涉及用于诊断胃癌的复合物，其含有测量CST1，DCC1，IFITM1或MELK的表达水平的制剂，含有所述复合物的试剂盒，检测所述标记物的方法和筛选方法使用所述标记治疗胃癌。

9. 发明申请

WO2009072831A3 NOVEL USE OF FLJ25416 GENE 审中-公开
标题翻译： FLJ25416基因的新用途
公开(公告)号：WO2009072831A3
公开(公告)日：2009-08-20
申请号：PCT/KR2008007196
申请日：2008-12-05
申请人： KOREA RES INST OF BIOSCIENCE , SAMCHULLY PHARM CO LTD , WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG-JOO , CHOI SHIN-JUNG , YEOM YOUNG IL , KIM SEON-YOUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , CHUN HO KYUNG , YUN CHAE-OK , KIM MOON HEE , JUNG KYEONG-EUN , CHO SUN-JUNG
发明人： WON MISUN , CHUNG KYUNG-SOOK , KIM YOUNG-JOO , CHOI SHIN-JUNG , YEOM YOUNG IL , KIM SEON-YOUNG , SONG KYUNG BIN , LEE HEE GU , SONG EUN YOUNG , KIM YOUNG HO , CHUN HO KYUNG , YUN CHAE-OK , KIM MOON HEE , JUNG KYEONG-EUN , CHO SUN-JUNG
IPC分类号： A61K38/17 , A61P35/00
CPC分类号： G01N33/57484 , A61K31/7088 , A61K38/1709 , C12N15/1135 , C12N15/86 , C12N2310/111 , C12N2310/14 , C12N2710/10343 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N2500/00 , G01N2500/04
摘要： Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.
摘要翻译：本发明提供了用于诊断癌症或筛选包含FLJ25416基因或针对由FLJ25416基因表达的蛋白质的抗体的抗癌药物的组合物，用于治疗癌症的组合物，所述组合物包含所述基因的抑制剂或由所述基因表达的蛋白质的抑制剂和药学上可接受的载体以及用于诊断癌症的试剂盒，其包含FLJ25416基因和由FLJ25416基因表达的蛋白质中的至少一种。 FLJ25416基因在特定癌细胞中高水平表达，并诱导正常细胞增殖速率增加。该基因的表达被抑制，这导致对癌细胞生长的抑制作用。因此，FLJ25416基因可以用作诊断或治疗癌症的靶基因。

10. 发明申请

WO2010093066A1 PPIA MARKER FOR DIAGNOSIS OF LIVER CANCER AND ANTIBODY, AND SCREENING METHOD OF COMPOUNDS USEFUL FOR INHIBITING LIVER CANCER 审中-公开
标题翻译：用于诊断肝癌和抗体的PPIA标记和用于抑制肝癌的化合物的筛选方法
公开(公告)号：WO2010093066A1
公开(公告)日：2010-08-19
申请号：PCT/KR2009/000614
申请日：2009-02-10
申请人： INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , KIM, Dae-Ghon , YU, Gyung-Ran , SONG, Eun-Young , LEE, Hee-Gu , YEOM, Young-Il , LEE, Jung-Il , KIM, Jae-Wha , JI, Na-Young
发明人： KIM, Dae-Ghon , YU, Gyung-Ran , SONG, Eun-Young , LEE, Hee-Gu , YEOM, Young-Il , LEE, Jung-Il , KIM, Jae-Wha , JI, Na-Young
IPC分类号： G01N33/574
CPC分类号： C07K16/30 , C12Q1/6886 , C12Q2600/158
摘要： Disclosed is a marker for diagnosis of liver cancer comprising polynucleotide useful for diagnosis of liver cancer. The marker for liver cancer diagnosis comprises at least one polynucleotide selected from a group consisting of the following polynucleotides (a) to (d): (a) polynucleotide having a base sequence defined by Seq. No. 1 or substantially similar sequence to Seq. No. 1; (b) polynucleotide encoding specific protein composed of an amino acid sequence defined by Seq. No. 2; (c) polynucleotide that comprises Seq. No. 2, in which at least one amino acid is substituted, deleted, inserted and/or added, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2; and (d) polynucleotide that is encoded by another polynucleotide hybridized with polynucleotide having Seq. No. 1 under stringent conditions, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2.
摘要翻译：公开了用于肝癌诊断的标志物，其包含可用于诊断肝癌的多核苷酸。用于肝癌诊断的标志物包含至少一种选自以下多核苷酸（a）至（d）的多核苷酸：（a）具有Seq。序号1或与Seq基本相似的序列。第1号（b）编码由Seq定义的氨基酸序列组成的特异性蛋白质的多核苷酸。第2号（c）包含Seq。 No.2，其中至少一个氨基酸被取代，缺失，插入和/或添加，并编码与Seq组成的特异性蛋白质功能等同的蛋白质。第2号和（d）由另外的多核苷酸编码的多核苷酸，其与具有Seq的多核苷酸杂交。在严格条件下编号1，编码与Seq组成的特异性蛋白质功能等同的蛋白质。第2号。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式